22 related articles for article (PubMed ID: 9544164)
1. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.
Borthakur G; Alvarado Y; Ravandi-Kashani F; Cortes J; Estrov Z; Faderl S; Ivy P; Bueso-Ramos C; Nebiyou Bekele B; Giles F
Cancer; 2008 Jul; 113(2):360-6. PubMed ID: 18473351
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer.
Goel S; Wadler S; Hoffman A; Volterra F; Baker C; Nazario E; Ivy P; Silverman A; Mani S
Invest New Drugs; 2003 Feb; 21(1):103-7. PubMed ID: 12795535
[TBL] [Abstract][Full Text] [Related]
3. MGI 114: augmentation of antitumor activity when combined with topotecan.
Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
Langevin AM; Bernstein M; Kuhn JG; Blaney SM; Ivy P; Sun J; Chen Z; Adamson PC;
Pediatr Blood Cancer; 2008 Mar; 50(3):577-80. PubMed ID: 17610262
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Tolcher AW; Eckhardt SG; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky EK
J Clin Oncol; 2001 Jun; 19(11):2937-47. PubMed ID: 11387367
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study.
Langevin AM; Weitman SD; Kuhn JG; Weintraub ST; Baruchel S; Furman W; Bernstein M; Blaney S; Vietti T;
J Pediatr Hematol Oncol; 2003 Jul; 25(7):526-33. PubMed ID: 12847318
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days.
Dowlati A; Hoppel CL; Ingalls ST; Majka S; Li X; Sedransk N; Spiro T; Gerson SL; Ivy P; Remick SC
J Clin Oncol; 2001 Apr; 19(8):2309-18. PubMed ID: 11304785
[TBL] [Abstract][Full Text] [Related]
8. Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles.
Long BH; Rose WC; Vyas DM; Matson JA; Forenza S
Curr Med Chem Anticancer Agents; 2002 Mar; 2(2):255-66. PubMed ID: 12678746
[TBL] [Abstract][Full Text] [Related]
9. In vitro assays of chemotherapeutic sensitivity.
Carney DN; Winkler CF
Important Adv Oncol; 1985; ():78-103. PubMed ID: 3916747
[TBL] [Abstract][Full Text] [Related]
10. Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development.
von Hoff DD
Cancer Metastasis Rev; 1988 Dec; 7(4):357-71. PubMed ID: 3061679
[TBL] [Abstract][Full Text] [Related]
11. In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors.
Weitman S; Moore R; Barrera H; Cheung NK; Izbicka E; Von Hoff DD
J Pediatr Hematol Oncol; 1998; 20(2):136-9. PubMed ID: 9544164
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
